Biophan wins new US patent

Biophan Technologies, a developer of next-generation medical technology, has received a new patent from the US Patent and Trademark Office that covers important operational aspects of the Myotech circulatory support system technology including critical control aspects of the drive unit.

According to Biophan, the Myotech circulatory support system (CSS) is a novel, non-blood contacting circulatory support system consisting of a flexible polymer cup which is inserted via an incision between two ribs. It is positioned around the lower half of the heart, avoiding direct contact with circulating blood, which is the primary cause of complications with competitive devices. 

An external drive unit actuates the CSS cup, providing active systolic and diastolic support. This design can be rapidly installed in less than five minutes. The speed of installation and lack of contact with circulating blood make the CSS a superior design for treating sudden cardiac arrest patients, the company said.

The company has pending application for additional patents that will cover future enhancements to the technology.

Biophan is currently seeking development and license partners to move the Myotech CSS forward into clinical trials. In addition, the company has multiple grant applications under review at the National Institutes of Health and Department of Defense to help support R&D of the CSS technology.

John Lanzafame, Biophan’s CEO, said: We are excited by the issuance of this patent, which greatly increases the value of our technology portfolio. This patent is the first US patent to issue covering the Myotech CSS technology, and is an important milestone for us.